Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| LEO Pharma GmbH, Neu-Isenburg, Germany | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this observational study is to evaluate the efficacy, tolerability, quality of life and handling of Daivobet® Gel by both physician and patient in daily practise.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Daivobet® Gel | Drug | Once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance. |
| Measure | Description | Time Frame |
|---|---|---|
| Handling of Daivobet® Gel | Compared to previous topical treatment: Time required for application (previous treatment versus present treatment), time required until dressing is possible (previous treatment versus present treatment) | After appr 4 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Quality of life | Dermatology Life Quality Index (DLQI) | 4 weeks |
| Physician's global Assessment of psoriasis vulgaris | 6-step scale from "no visible disease (O)" to "very severe disease (5) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients visiting their attending dermatologist in the primary care clinic
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Michael Sticherling, Prof dr med | University clinic Erlangen-Nuernberg | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Clinic of Erlangen Nuernberg | Erlangen | 91054 | Germany |
Not provided
Not provided
Not provided
Not provided
| 4 weeks |
| Side effects | number of participants with serious and non-serious adverse drug reactions, according to organ classes | 4 weeks |